Main Menu Jump to Page

Chemed公司("CHE")

罗森律师事务所正在调查Chemed公司涉嫌违反了联邦证券法。该公司的Vitas临终关怀业务故意向政府免费医疗保险Medicare项目多收取费用。

2013年5月2日,美国司法部起诉Chemed,声称Chemed故意向Medicare保险多申报账单,或者申报未提供服务的假账单,或者向根本不符合Medicare资格的病人提供服务并向Medicare申报账单。该消息曝光后,Chemed的股票下跌逾15%。

如果您在2013年5月2日前购买了Chemed的股票,请点击上述“参加集体诉讼”。

新闻公告

The Rosen Law Firm Announces Investigation of Securities ClaimsAgainst Chemed Corporation – CHE

New York, N.Y., May 21, 2013.  The Rosen Law Firm announces that it is investigating potential securities claims against Chemed Corporation (the "Company") (NYSE: CHE) resulting from allegations that Chemed’s Vitas hospice business knowingly overbilled the Medicare program. 

Vitas is the largest for-profit hospice care chain in the United States.  It was acquired by Chemed in 2004.  On May 2, 2013, the United States Department of Justice (“DOJ”) filed a lawsuit against Chemed and its affiliates alleging the Company violated the False Claims Act by systematically defrauding Medicare.  Specifically, the DOJ’s complaint alleges that Chemed knowingly submitted or caused the submission of false Medicare claims for hospice services that were unnecessary, were not provided, or were provided to patients who were ineligible under Medicare requirements.  As a result of this news, Chemed shares fell over 15%.

The Rosen Law Firm is investigating a securities class action lawsuit on behalf of Chemed investors.  If you purchased Chemed stock before May 2, 2013, please visit the website at http://rosenlegal.com for more information.  You may also contact Jonathan Horne, Esq., or Phillip Kim, Esq. of The Rosen Law Firm toll free at 866-767-3653 or via e-mail at jhorne@rosenlegal.com or pkim@rosenlegal.com.

The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.

Attorney Advertising.  Prior results do not guarantee a similar outcome.